Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Phase 1

Completed

Conditions: Advanced/Metastatic Tumors

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Capecitabine
Drug: Bevacizumab
Drug: Cisplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Etoposide

First Posted Date: 2016-06-09

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 518

Registration Number: NCT02794571

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 25 locations

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Phase 1

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Atezolizumab
Biological: Bacille Calmette-Guérin

First Posted Date: 2016-06-07

Last Posted Date: 2021-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT02792192

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
VA Portland Healthcare System, Portland, Oregon, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 5 locations

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Advanced Non-Clear Cell Kidney Cancer

Interventions: Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2016-03-31

Last Posted Date: 2024-12-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT02724878

Locations: 🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab
Drug: 5-FU
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Nab-Paclitaxel
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2016-03-22

Last Posted Date: 2021-07-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 243

Registration Number: NCT02715531

Locations: 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 27 locations

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Entinostat
Drug: Atezolizumab
Drug: Placebo

First Posted Date: 2016-03-15

Last Posted Date: 2024-12-04

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT02708680

Locations: 🇺🇸
Ft. Wayne Hematology and Oncology, Fort Wayne, Indiana, United States
🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸
Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States

and more 26 locations

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: Bevacizumab
Drug: atezolizumab
Drug: placebo
Drug: acetylsalicylic acid

First Posted Date: 2016-01-20

Last Posted Date: 2023-03-14

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 122

Registration Number: NCT02659384

Locations: 🇳🇱
Leiden University Medical Centre, Leiden, Netherlands
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇬🇧
Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London, United Kingdom

and more 9 locations

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2016-01-15

Last Posted Date: 2023-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 578

Registration Number: NCT02657434

Locations: 🇺🇸
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸
Oncology Consultants PA, Houston, Texas, United States

and more 180 locations

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Atezolizumab
Drug: RO6958688

First Posted Date: 2016-01-08

Last Posted Date: 2020-02-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 228

Registration Number: NCT02650713

Locations: 🇺🇸
UCLA Cancer Center, Santa Monica, California, United States
🇺🇸
Stanford Comprehensive Cancer Center, Stanford, California, United States
🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark

and more 21 locations

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1

Completed

Conditions: HER2-Positive Metastatic Breast Cancer
HER2-Negative Metastatic Breast Cancer
Locally Advanced or Early Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Pertuzumab
Drug: Trastuzumab emtansine
Drug: Doxorubicin
Drug: Docetaxel
Drug: Carboplatin
Drug: Trastuzumab
Drug: Cyclophosphamide

First Posted Date: 2015-11-16

Last Posted Date: 2020-02-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 98

Registration Number: NCT02605915

Locations: 🇺🇸
HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸
Horizon Oncology Research, Inc., Lafayette, Indiana, United States
🇺🇸
St. Luke's University Health Network, Bethlehem, Pennsylvania, United States

and more 17 locations

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage I Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2015-11-06

Last Posted Date: 2023-07-03

Lead Sponsor: Megan Daly, MD

Target Recruit Count: 20

Registration Number: NCT02599454

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
David Grant United States Air Force Medical Center, Travis Air Force Base, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy